22:26 , May 18, 2017 |  BC Innovations  |  Targets & Mechanisms

Degrading NASH

Inflammation is one of the primary drivers of non-alcoholic steatohepatitis (NASH), but decreasing inflammation without creating susceptibility to infection remains a challenge for the field. In Nature Medicine this month, a Chinese team described how...
18:33 , Mar 31, 2017 |  BC Week In Review  |  Company News

Ionis to spin out lipid company Akcea

Ionis plans to spin out subsidiary Akcea Therapeutics Inc. in an IPO in which it would raise up to $100 million. Concurrently, partner Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) will invest $50 million in Akcea...
23:50 , Mar 27, 2017 |  BC Extra  |  Financial News

Ionis lipid spinout Akcea targets $100M IPO

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) plans to spin out subsidiary Akcea Therapeutics Inc. in an IPO in which it would raise up to $100 million, according to a regulatory filing. Concurrently, partner Novartis AG (NYSE:NVS; SIX:NOVN)...
07:00 , Mar 24, 2016 |  BC Innovations  |  Product R&D

Liver-bound

Ionis Pharmaceuticals Inc. is retooling its antisense technology with a sugar-based conjugate that boosts uptake into liver cells. By tapping the power of GalNAc sugars to latch onto hepatocyte receptors, the company believes it can...